title: Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.
abstract: BACKGROUND
  To evaluate if peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo.
  
  
  METHODS
  Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls.
  
  
  RESULTS
  Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway.
  
  
  CONCLUSIONS
  The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.
authors.affiliation: Divisions of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Yao
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Pawlaczyk
authors.forename: Ernesto Rodríguez
authors.initials: ER
authors.lastname: Ayala
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kuzlan
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Styszynski
authors.forename: Andrzej
authors.initials: A
authors.lastname: Breborowicz
authors.forename: Olof
authors.initials: O
authors.lastname: Heimburger
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Qian
authors.forename: Peter
authors.initials: P
authors.lastname: Stenvinkel
authors.forename: Jonas
authors.initials: J
authors.lastname: Axelsson
authors.forename: Bengt
authors.initials: B
authors.lastname: Lindholm
mesh_terms: D000818:Animals; D015312:Hemodialysis Solutions / Q000009:adverse effects* / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D047495:PPAR gamma / Q000037:antagonists & inhibitors*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D015398:Signal Transduction / Q000187:drug effects; D051785:Smad Proteins / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology*; D015291:Transforming Growth Factors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015312:Hemodialysis Solutions; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D051785:Smad Proteins; D045162:Thiazolidinediones; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000077154:Rosiglitazone; D015291:Transforming Growth Factors